NewAmsterdam Pharma Company N.V. (NAMS) News
Track canonical SquawkNews coverage tagged to NAMS, NewAmsterdam Pharma Company N.V.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
NAMS Initiated Outperform and $58 PT @ BMO
NAMS Initiated Outperform and $58 PT @ BMO
EQUITY | Jul 21, 2026, 12:42 PM UTC
L
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Raises Price Target to $51
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ: NAMS ) with a Outperform and raises the price target from $47 to $51.
EQUITY | Jun 30, 2026, 03:33 PM UTC